Drugs / NLS-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05914194 | Jul 2024 → Jul 2025 | narcolepsy 1 | NLS Pharmaceutics | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NLS-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05914194 ↗ |
| Route | Oral | “Participants will receive NLS-2 tablets orally.” NCT05914194 ↗ |